Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Orphanet Journal of Rare Diseases

Fixed-cycle oral pomalidomide/lenalidomide-based therapy is associated with durable treatment-free remission in idiopathic multicentric castleman disease with TAFRO syndrome: a single-center retrospective study

  1. 1Department of Hematology, Peking University First Hospital, Beijing, 100034 China
  2. 2Department of Nephrology, Peking University First Hospital, Beijing, 100034 China
  3. 3Department of Pathology, Peking University First Hospital, Beijing, 100034 China

Abstract

Background: Idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO) is a rare and severe subtype of iMCD characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Current treatments often require prolonged or indefinite administration and frequent hospital visits, imposing substantial burdens on patients. We evaluated the clinical outcomes and safety of a fixed-cycle oral immunomodulatory drug (IMiD)-based regimen in patients with iMCD-TAFRO.

Methods: In this single-center retrospective study, seven patients with iMCD-TAFRO who received an oral immunomodulatory drug (IMiD)-based fixed-cycle regimen were analyzed. Six patients received pomalidomide-dexamethasone or lenalidomide-dexamethasone without concurrent intravenous therapy, whereas one patient received pomalidomide-dexamethasone plus concurrent siltuximab as the initial treatment strategy. The primary endpoint was the overall response rate (ORR) at the prespecified 8-week (± 2 weeks) assessment window. Key secondary endpoints included paired changes in C-reactive protein (CRP), albumin, platelet count, and serum creatinine (Scr) from baseline to month 2. Best overall response was analyzed as an exploratory endpoint.

Results: At the 8-week assessment, four of seven patients achieved a partial response (ORR, 57.1%; 95% CI, 18.4–90.1%), while three had stable disease; no complete responses were observed at this time point. With continued therapy and follow-up, all seven patients achieved complete response as their best overall response (best ORR, 100%; 95% CI, 59.0-100.0%). The median time to initial response was 2.0 months (IQR, 2.0-3.5). Paired analyses from baseline to month 2 demonstrated statistically significant changes in CRP, albumin, and serum creatinine, whereas platelet counts showed numerical improvement without reaching statistical significance. The median treatment duration was 6 months (range, 2–12). Six patients remained in treatment-free remission at last follow-up, with a median treatment-free remission duration of 15.5 months (range, 4–39). One patient relapsed after a prolonged TTNT of 84 months from treatment initiation. Grade 3 adverse events were limited to hyperbilirubinemia (n = 1) and febrile neutropenia (n = 1); no thromboembolic events or secondary malignancies occurred.

Conclusions: This fixed-cycle oral IMiD-based regimen, with or without concurrent anti-IL-6 therapy in selected cases, was associated with encouraging clinical and laboratory responses in patients with iMCD-TAFRO, including improvements in inflammatory markers, vascular leak, and renal function. Durable treatment-free remission after a finite course of therapy was observed in most patients in this cohort. Given the retrospective design and limited sample size, these findings should be interpreted cautiously and require confirmation in larger multicenter prospective studies.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13023-026-04516-x.

Related

  1. Characteristics of idiopathic multicentric Castleman disease in Spain: results of the registry-based ARCANA multicenter study
    Jose-Tomas Navarro, Santiago Montes-Moreno, Grisell Starita Fajardo +15
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMCEurope PMC
  2. Idiopathic Multicentric Castleman Disease Presenting With Generalized Lymphadenopathy: A Case Report
    Alma P Huerta Alvarado, Oliver Colis Arenas, Yesenia Ortega Flores +4
    CureusPeer-reviewedCC BY 4.0Full textOncologyPMC
  3. Kidney involvement in idiopathic multicentric Castleman disease-TAFRO syndrome: clinical spectrum, pathology and outcomes.
    Shuo Zhang, Hanshu Liu, Siyuan Li +13
    Clinical kidney journalPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Idiopathic Multicentric Castleman Disease Mimicking Sepsis and Autoimmune Disease in a Caribbean Patient
    Amber S Maharaj
    CureusPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  5. Blood-based biomarkers associated with progressive pulmonary fibrosis in idiopathic inflammatory myositis-associated interstitial lung disease: A retrospective cohort study from a respiratory center
    Mayuko Ishiwari, Yuta Kono, Kenichi Kobayashi +4
    Multidisciplinary Respiratory MedicinePeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
BibTeX
@article{bo2026fixedcycle,
  title = {{Fixed-cycle oral pomalidomide/lenalidomide-based therapy is associated with durable treatment-free remission in idiopathic multicentric castleman disease with TAFRO syndrome: a single-center retrospective study}},
  author = {Tang Bo and Xie Shuanglian and Yu Xiaojuan and Wang Wei and Shen Ye and Di Mingyi and Sun Yuhua and Liu Wei and Dong Yujun},
  journal = {Orphanet Journal of Rare Diseases},
  year = {2026},
  month = aug,
  doi = {10.1186/s13023-026-04516-x},
  url = {https://doi.org/10.1186/s13023-026-04516-x},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Fixed-cycle oral pomalidomide/lenalidomide-based therapy is associated with durable treatment-free remission in idiopathic multicentric castleman disease with TAFRO syndrome: a single-center retrospective study
AU  - Tang Bo
AU  - Xie Shuanglian
AU  - Yu Xiaojuan
AU  - Wang Wei
AU  - Shen Ye
AU  - Di Mingyi
AU  - Sun Yuhua
AU  - Liu Wei
AU  - Dong Yujun
PY  - 2026
DA  - 2026/08/08
JO  - Orphanet Journal of Rare Diseases
DO  - 10.1186/s13023-026-04516-x
UR  - https://doi.org/10.1186/s13023-026-04516-x
AB  - Background: Idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO) is a rare and severe subtype of iMCD characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly. Current treatments often require prolonged or indefinite administration and frequent hospital visits, imposing substantial burdens on patients. We evaluated the clinical outcomes and safety of a fixed-cycle oral immunomodulatory drug (IMiD)-based regimen in patients with iMCD-TAFRO.  Methods: In this single-center retrospective study, seven patients with iMCD-TAFRO who received an oral immunomodulatory drug (IMiD)-based fixed-cycle regimen were analyzed. Six patients received pomalidomide-dexamethasone or lenalidomide-dexamethasone without concurrent intravenous therapy, whereas one patient received pomalidomide-dexamethasone plus concurrent siltuximab as the initial treatment strategy. The primary endpoint was the overall response rate (ORR) at the prespecified 8-week (± 2 weeks) assessment window. Key secondary endpoints included paired changes in C-reactive protein (CRP), albumin, platelet count, and serum creatinine (Scr) from baseline to month 2. Best overall response was analyzed as an exploratory endpoint.  Results: At the 8-week assessment, four of seven patients achieved a partial response (ORR, 57.1%; 95% CI, 18.4–90.1%), while three had stable disease; no complete responses were observed at this time point. With continued therapy and follow-up, all seven patients achieved complete response as their best overall response (best ORR, 100%; 95% CI, 59.0-100.0%). The median time to initial response was 2.0 months (IQR, 2.0-3.5). Paired analyses from baseline to month 2 demonstrated statistically significant changes in CRP, albumin, and serum creatinine, whereas platelet counts showed numerical improvement without reaching statistical significance. The median treatment duration was 6 months (range, 2–12). Six patients remained in treatment-free remission at last follow-up, with a median treatment-free remission duration of 15.5 months (range, 4–39). One patient relapsed after a prolonged TTNT of 84 months from treatment initiation. Grade 3 adverse events were limited to hyperbilirubinemia (n = 1) and febrile neutropenia (n = 1); no thromboembolic events or secondary malignancies occurred.  Conclusions: This fixed-cycle oral IMiD-based regimen, with or without concurrent anti-IL-6 therapy in selected cases, was associated with encouraging clinical and laboratory responses in patients with iMCD-TAFRO, including improvements in inflammatory markers, vascular leak, and renal function. Durable treatment-free remission after a finite course of therapy was observed in most patients in this cohort. Given the retrospective design and limited sample size, these findings should be interpreted cautiously and require confirmation in larger multicenter prospective studies.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13023-026-04516-x.
SN  - 1750-1172
ER  -